TETARD, Candice; MITTAINE, Marie; BUI, Stephanie; BEAUFILS, Fabien; MAUMUS, Pascale; FAYON, Michael; BURGEL, Pierre-Regis; LAMIREAU, Thierry; DELHAES, Laurence; MAS, Emmanuel; ENAUD, Raphael

doi:10.1097/MPG.0000000000002864

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Journal of Pediatric Gastroenterology and Nutrition. 2020-12, vol. 71, n° 6, p. 778-781

Résumé en anglais

A chronic intestinal inflammation may occur in patients with cystic fibrosis (CF), while no therapeutic management is proposed. Although Lumacaftor/Ivacaftor is well-known to modulate the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein in lungs, no data are available on the impact of this treatment on CF intestinal disorders. We, therefore, investigated the evolution of intestinal inflammation after initiation of Lumacaftor/Ivacaftor in CF adolescents (median of follow-up: 336 days [IQR: 278;435]). Median fecal calprotectin concentrations decreased significantly after Lumacaftor/Ivacaftor initiation (102 ?g/g [IQR: 69-210]) compared with the baseline (713 ?g/g (IQR:148-852), P = 0.001). To our knowledge, this study showed for the first time that CF-related intestinal inflammation is improved by Lumacaftor/Ivacaftor treatment.< Réduire

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche